Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: DOLLAR BILL who wrote (26802)	12/8/1998 3:10:00 AM
From: Henry Niman	Respond to of 32384

As I said earlier, the key questions on ONTAK and Panretin are more a matter of when than if. Lately (a couple of years), LGND has been more of a buy on rumor, sell on news type of stock, and most of the news had been widely anticipated. I'm not sure how many expect both approvals to come this year. If both were announced very close together, then the price could jump. If announced apart, then the one not announced could hold back the price. Moreover, LGND has promised quite a bit of clinical data for some time now. The latest promises have been "this year", which of course dove tails with the above two and is now really "this month". With many announcements anticipated, price movement may be limited due to the outstanding news items.